Beacon Pointe Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$383K	Buy	1,157 +367	+46%	+$125K	﹤0.01%	1412
2025 Q4	$314K	Sell	790 -164	-17%	-$72.6K	﹤0.01%	1245
2025 Q3	$435K	Sell	954 -82	-8%	-$33.4K	﹤0.01%	1053
2025 Q2	$338K	Buy	1,036 +169	+19%	+$46.8K	﹤0.01%	1001
2025 Q1	$234K	Sell	867 -68	-7%	-$17.5K	﹤0.01%	1104
2024 Q4	$220K	Sell	935 -440	-32%	-$116K	﹤0.01%	1115
2024 Q3	$378K	Sell	1,375 -137	-9%	-$35.7K	﹤0.01%	949
2024 Q2	$367K	Sell	1,512 -124	-8%	-$19.6K	﹤0.01%	988
2024 Q1	$245K	Hold	1,636	–	–	﹤0.01%	1181
2023 Q4	$313K	Sell	1,636 -55	-3%	-$9.37K	﹤0.01%	1065
2023 Q3	$299K	Buy	1,691 +111	+7%	+$21.2K	﹤0.01%	1066
2023 Q2	$300K	Sell	1,580 -126	-7%	-$25K	﹤0.01%	886
2023 Q1	$342K	Sell	1,706 -84	-5%	-$17.7K	0.01%	888
2022 Q4	$425K	Buy	1,790 +33	+2%	+$7.04K	0.01%	746
2022 Q3	$351K	Buy	1,757 +156	+10%	+$29.8K	0.01%	751
2022 Q2	$235K	Sell	1,601 -139	-8%	-$19.7K	0.01%	916
2022 Q1	$284K	Buy	1,740 +395	+29%	+$60.2K	﹤0.01%	1001
2021 Q4	$228K	Sell	1,345 -205	-13%	-$38.1K	0.01%	831
2021 Q3	$293K	Buy	+1,550	New	+$291K	0.01%	716